After Madison Norman graduated with an undergraduate degree in business administration from Boston University and then a ...

Trust in pharma has always been fragile, and the rise of misinformation has made it even more precarious. | Freda Lewis-Hall, ...

Explore 16 creative examples from across life sciences, including launches, rebrands, data-led storytelling, and campaign design. | Explore 16 creative examples from across life sciences, including ...

Europe offers major opportunities for biotech and pharmaceutical companies, but breaking into the market is complicated by a patchwork of regulations, reimbursement systems and distribution networks.

MilliporeSigma, a unit of Germany's Merck KGaA, opened a 150 million euro ($177 million) filtration products plant in Cork, bolstering the company’s goal to expand global manufacturing operations. The ...

Medical affairs is on the brink of transformation. Learn how AI is reshaping evidence generation, scientific engagement, and strategic planning. Get the roadmap to prepare your team for what's next ...

Takeda, coming off a high of 2024 growth, is pushing through what it says will be the worst of its Vyvanse-related declines. The company’s quarterly revenues from April to June sank 8.4% to 1.1 ...

Since its historic FDA approval in March 2024 as the first medication for the treatment of the prevalent liver disease metabolic dysfunction-associated steatohepatitis (MASH), Madrigal Pharmaceuticals ...

With another quarter exceeding analysts’ expectations, Blueprint Medicines has raised its peak sales estimate for rare disease drug Ayvakit to $2 billion. The Massachusetts biotech unveiled the new ...